kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Company profile
Ticker
KZR
Exchange
Website
CEO
John Fowler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
KZR stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
424B5
Prospectus supplement for primary offering
22 Mar 24
S-8
Registration of securities for employees
14 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
14 Mar 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
27 Oct 23
Transcripts
Latest ownership filings
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G
BARCLAYS PLC
14 Feb 24
SC 13G/A
Avidity Partners Management LP
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
Prosight Management, LP
13 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
22 Jan 24
3
Mark C. Schiller
17 Jan 24
4
Marc Belsky
9 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.50 mm | 26.50 mm | 26.50 mm | 26.50 mm | 26.50 mm | 26.50 mm |
Cash burn (monthly) | 537.00 k | 3.16 mm | 8.51 mm | 8.07 mm | 6.74 mm | 6.55 mm |
Cash used (since last report) | 3.64 mm | 21.46 mm | 57.72 mm | 54.76 mm | 45.69 mm | 44.40 mm |
Cash remaining | 22.86 mm | 5.04 mm | -31.22 mm | -28.26 mm | -19.19 mm | -17.90 mm |
Runway (months of cash) | 42.6 | 1.6 | -3.7 | -3.5 | -2.8 | -2.7 |
Institutional ownership, Q3 2023
88.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 83 |
Opened positions | 6 |
Closed positions | 29 |
Increased positions | 35 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 64.48 bn |
Total shares | 64.43 mm |
Total puts | 574.50 k |
Total calls | 722.10 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Suvretta Capital Management | 7.17 mm | $8.53 bn |
Morningside Venture Investments | 6.25 mm | $9.63 mm |
Avidity Partners Management | 6.01 mm | $7.15 bn |
Orbimed Advisors | 5.46 mm | $6.50 bn |
BLK Blackrock | 4.95 mm | $5.89 bn |
Prosight Management | 4.77 mm | $5.68 bn |
Millennium Management | 3.40 mm | $4.05 bn |
Vanguard | 3.04 mm | $3.62 bn |
BBBOF BB Biotech | 3.00 mm | $0.00 |
Sphera Funds Management | 2.05 mm | $2.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Jan 24 | Nicholas Michael Mordwinkin | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.93 | 275,000 | 255.75 k | 275,000 |
7 Jan 24 | Marc Belsky | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.93 | 295,000 | 274.35 k | 295,000 |
8 Nov 23 | Christopher J. Kirk | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.84 | 875,000 | 735.00 k | 875,000 |
15 Aug 23 | Morningside Venture Investments | Common Stock | Gift | Dispose G | No | No | 0 | 3,500,000 | 0.00 | 1,947,993 |
Press releases
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8 Apr 24
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
14 Mar 24
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8 Mar 24
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
28 Feb 24
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
26 Feb 24